AbbVie Inc
4AB
Company Profile
Business description
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Contact
1 North Waukegan Road
North ChicagoIL60064-6400
USAT: +1 847 932-7900
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
55,000
Stocks News & Analysis
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,375.90 | 19.70 | 0.21% |
| CAC 40 | 8,139.20 | 62.20 | 0.77% |
| DAX 40 | 24,152.14 | 29.23 | -0.12% |
| Dow JONES (US) | 46,340.54 | 87.23 | 0.19% |
| FTSE 100 | 9,396.86 | 27.89 | -0.30% |
| HKSE | 25,888.51 | 22.09 | -0.09% |
| NASDAQ | 22,789.64 | 119.56 | 0.53% |
| Nikkei 225 | 48,277.74 | 605.07 | 1.27% |
| NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
| S&P 500 | 6,689.00 | 17.94 | 0.27% |
| S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
| SSE Composite Index | 3,916.23 | 4.02 | 0.10% |